Last reviewed · How we verify

Spinal Block

Meir Medical Center · FDA-approved active Small molecule Quality 5/100

Spinal Block, marketed by Meir Medical Center, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established patient base and physician recognition. The primary risk is the potential increase in competition post-patent expiry in 2028, which could erode market share and revenue.

At a glance

Generic nameSpinal Block
Also known asNeurological block
SponsorMeir Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: